Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 135


Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy.

Bains P, Al Tourah A, Campbell BA, Pickles T, Gascoyne RD, Connors JM, Savage KJ.

Ann Oncol. 2013 Feb;24(2):428-32. doi: 10.1093/annonc/mds433. Epub 2012 Oct 3.


Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.

Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, MacDonald DA, Buckstein R, Lee C, Alzahrani M, Rubinger M, Foley R, Xenocostas A, Sabloff M, Muccilli A, Chua N, Couture F, Larouche JF, Cohen S, Connors JM, Ambler K, Al-Tourah A, Ramadan KM, Kuruvilla J.

J Clin Oncol. 2013 Mar 20;31(9):1164-71. doi: 10.1200/JCO.2012.44.0693. Epub 2013 Feb 11.


Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation.

Guckenberger M, Alexandrow N, Flentje M.

Radiat Oncol. 2012 Jun 24;7:103. doi: 10.1186/1748-717X-7-103.


High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.


Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy.

Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, Stevenson MA, Mauch P.

Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928-34. Epub 2005 Oct 21.


Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.

Hirayama Y, Ishitani K, Ota S, Kurosawa M, Kondo T, Takimoto R, Mori A, Sakai H, Torimoto Y, Yamamoto S, Sato K, Iwasaki H, Kohda K, Ishida T, Kakinoki Y, Fukuhara T, Kato J.

Int J Hematol. 2014 Sep;100(3):281-9. doi: 10.1007/s12185-014-1629-4. Epub 2014 Jul 23.


Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.

Peters AC, Duan Q, Russell JA, Duggan P, Owen C, Stewart DA.

Leuk Lymphoma. 2011 Nov;52(11):2124-9. doi: 10.3109/10428194.2011.594925. Epub 2011 Jul 8.


Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients.

Fakhrian K, Klemm S, Keller U, Bayer C, Riedl W, Molls M, Geinitz H.

Strahlenther Onkol. 2012 Jun;188(6):464-70. doi: 10.1007/s00066-011-0057-0. Epub 2012 Feb 16. Erratum in: Strahlenther Onkol. 2013 Feb;189(2):168.


New treatment options have changed the survival of patients with follicular lymphoma.

Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.

J Clin Oncol. 2005 Nov 20;23(33):8447-52. Epub 2005 Oct 17.


The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.

Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR.

Cancer. 2014 Jun 15;120(12):1830-7. doi: 10.1002/cncr.28659. Epub 2014 Mar 25.


Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G; GELA and GOELAMS.

Haematologica. 2011 Aug;96(8):1128-35. doi: 10.3324/haematol.2010.030320. Epub 2011 Apr 12.


Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.

Barzenje DA, Cvancarova Småstuen M, Liestøl K, Fosså A, Delabie J, Kolstad A, Holte H.

PLoS One. 2015 Jul 6;10(7):e0131158. doi: 10.1371/journal.pone.0131158. eCollection 2015.


Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.

Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, Merli F, Vallisa D, Baldini L, Brugiatelli M; Italian Lymphoma Study Group.

Cancer. 2007 May 15;109(10):2077-82.


Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma.

Ott OJ, Rödel C, Gramatzki M, Niedobitek G, Sauer R, Grabenbauer GG.

Strahlenther Onkol. 2003 Oct;179(10):694-701.


The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.

Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD.

Blood. 2010 Jan 14;115(2):289-95. doi: 10.1182/blood-2009-07-235598. Epub 2009 Nov 9.


Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.

Nicolas-Virelizier E, Ségura-Ferlay C, Ghesquières H, Chassagne-Clément C, Gargi T, Biron P, Belhabri A, Rey P, Faurie P, Chabaud S, Sebban C.

Hematol Oncol. 2015 Mar;33(1):1-8. doi: 10.1002/hon.2130. Epub 2014 Feb 5.


Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.

Hainsworth JD, Greco FA, Raefsky EL, Thompson DS, Lunin S, Reeves J Jr, White L, Quinn R, DeBusk LM, Flinn IW.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):277-83. doi: 10.1016/j.clml.2014.02.010. Epub 2014 Feb 28.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk